Skip to main content
. 2012 Sep;5(5):255–266. doi: 10.1177/1756285612453972

Figure 2.

Figure 2.

Disposition of patients in the phase II study by Novotna et al. [2011].

A total of 660 patients with multiple sclerosis were screened and 572 enrolled into a single-blind phase during which all patients received nabiximols; 538 patients completed 4 weeks of treatment. All responders (n = 241) were randomised into a second double-blind phase, during which 124 patients received nabiximols and 117 placebo.